Quick-Med Technologies, a life sciences company, has gained a new patent for its NIMBUS technology from the patent office of Mexico (Instituto Mexicano de la Propiedad Industrial).

NIMBUS is an antimicrobial technology which has been designed for wound care and other medical applications.

The Mexican patent covers the method of production that non-leachably bonds NIMBUS antimicrobials to various treated substrates.

The production method deals with the process of attaching members of the NIMBUS family of antimicrobials to substrates that are whole or in part cellulosic, or any of a list of other substrates such as polymerics, as well as silk, linen, rubber, alginates and collagen, among many others.

"NIMBUS is an antimicrobial technology which has been designed for wound care and other medical applications."

Jerry Olderman, Quick-Med R&D vice president, said the non-leachable bonding of the antimicrobial agent distinguishes NIMBUS from other antimicrobial materials which require the release of the active agent in order to function.

"This patent covers the process of treating materials such that they become permanent barriers to the transmission of microorganisms," Olderman added.

The patent, entitled Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate, remains effective until 22 August 2026.

The technology has won similar patents in the US, South Africa, Australia and has others pending in Canada, China, Europe, India, and Japan.

According to the company, the bonding of an antimicrobial to a substrate is a paradigm shift from current state-of-the-art methods which encourage the release of the active agent.

The non-leaching antimicrobial does not allow depletion of the active agent that leads to human skin or tissue cell damage, by causing irritation, delayed healing and possibly initiating the development of bacterial resistance.